The Group's principal activities are developing and manufacturing recombinant therapeutic proteins that are produced through our proprietary ProCellEx(TM) protein expression system. The Group's product prGCD is a proprietary plant cell expressed recombinant form of Glucocerebrosidase (GCD) for the treatment of Gaucher Disease, a lysosomal storage disorder in humans. It has completed a Phase I clinical trial on prGCD, and is exempt from Phase II. In July 2007, the Group reached an agreement with the FDA on the final design of pivotal phase III clinical trial of prGCD. The Group operates in Carmiel, Israel.
Alacra Alerts:
Receive alerts on the latest reports on Protalix BioTherapeutics Inc
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
